Roche’s Tecentriq Receives CHMP’s Positive Opinion for 1L Treatment for Metastatic Non-Small Cell Lung Cancer

March 29, 2021 Auto Bot 1L, CHMP, Metastatic, Non-Small Cell Lung Cancer, Positive Opinion, Receive, regulatory, Roche, Tecentriq 0

Shots:

  • The CHMP’s recommendation is based on Phase III IMpower110 study assessing Tecentriq vs CT  in 572 PD-L1-selected, CT-naïve participants in a ratio (1:1) with stage IV non-squamous or squamous NSCLC
  • Results: OS in people with high PD-L1 expression (7.1 vs 3.1mos.); safety profile is consistent with the current profile & no new safety signals were identified
  • If approved, Tecentriq could provide people with a specific type of lung cancer a chemotherapy-free option in the 1L treatment setting

Click here ­to­ read full press release/ article | Ref: Roche | Image: Pharma Live

The post Roche’s Tecentriq Receives CHMP’s Positive Opinion for 1L Treatment for Metastatic Non-Small Cell Lung Cancer first appeared on PharmaShots.